This collection consists of serum, whole blood and swabs from patients with kidney disease, including patients with acute kidney injury, glomerulonephritis and polycystic kidney disease. This collection also includes surplus arterial tissue collected from pre-dialysis and dialysis patients during (i) arteriovenous fistula surgery and (ii) limb amputation surgery for peripheral artery disease. Chronic kidney disease is associated with a number of serious complications, including an increased risk of (i) cardiovascular disease (ii) bone forming in the blood vessel wall (vascular calcification) (iii) a reduced red blood cell count (anaemia) (iv) metabolic bone disease There are limited treatment options for some of these serious complications in patients with chronic kidney disease – in particular vascular calcification. This collection will provide a resource for researchers investigating kidney disease and/or vascular complications in kidney disease, and will help researchers understand if the levels and/or activity of specific proteins are changed in this disease. This collection of samples could also be used in improving our understanding of the pathophysiology of kidney diseases (including longitudinal samples). The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): Genetic studies Immunological studies Multi-morbidity studies Biomarker studies Functional analysis of cells – surplus tissue collection from surgery in patients with kidney disease (such as peritoneal catheter insertion, arterio-venous fistula creation, parathyroidectomy)

The Northern Care Alliance Research Collection (NCARC) includes a biobank to explore novel application of laboratory biomarkers in Inherited Metabolic Diseases. The collection population comprises patients with rare metabolic diseases such as Mucopolysaccharidosis, Alpha-Mannosidosis, Mucolipidosis, Pompe Disease, Fabry Disease, Gaucher Disease, Phenylketonuria, Urea Cycle Disorders, Organic Acidaemia, mitochondrial diseases and many others. The collection consists of whole blood, serum, plasma and citrate plasma samples as well as associated clinical data from both primary and secondary care settings. The collection allows scope for adjustment to the sample type through NCARC’s simple amendment process. This collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research in establishing prognostic markers of cardiovascular disease, bone health, renal disease and acute illness among rare diseases. There is potential to improve the method and time taken for diagnosis, prognostication and treatment monitoring with refinement of laboratory processing and biomarker discovery. Our biological samples have been processed and stored under conditions that reflect the current best practise to maximise the integrity and security of the samples and ensure compliance with current regulatory requirements. The biological samples collected will enable a number of different analyses to be performed. This may include (but not limited to): • Biomarker studies • Multi-morbidity studies • Biomedical device development

The diabetes and endocrine collection of serum, whole blood and swabs from patients with diabetic foot ulcerswill provide an important resource for endocrine, diabetic and testosterone replacement research in the future that has the potential to benefit patients with rare manifestations of diabetes and endocrine disorders. At the NCA we see many patients with rare endocrine conditions such as Congenital Adrenal Hyperplasia, Conn’s Syndrome and Premature Ovarian Failure as well as people who have not responded to the usual treatment approach, such as those with treatment unresponsive hypothyroidism and severe polycystic ovarian syndrome. This collection aims to provide a genetic and serological repository that will be available for academic and commercial research teams to undertake studies so that we can better understand the aetiology and potential optimal therapeutic strategies for managing these conditions. The biological samples collected will enable a number of different analyses to be performed. This may include (but is not limited to): Genetic studies Biomarker studies Functional analysis of cells

NCARC has a growing collection of blood and cerebrospinal fluid samples in patients with idiopathic normal pressure hydrocephalus (iNPH). There is an associated research database with clinical, neuropsychological and imaging data. iNPH lacks a good understanding of the cause of the condition. The iNPH collection aims to promote research into the discovery of new biomarkers by providing biomaterial to academic and commercial researchers/partners, to enable investigation into the underlying cause of the condition using the most advanced scientific methods thereby improving diagnosis and treatment.

The neurodegenerative dementias collection of serum, whole blood and swabs from patients with neurodegenerative diseases could be used in improving our understanding of the genetic basis of neurodegenerative diseases, for example those causing dementia. In addition, the samples could support the development of blood biomarker technology with the aim of earlier and more accurate diagnosis of these disorders. Biomarkers may also be developed that allow tracking of disease progression with time – samples collected from the same individuals over various time intervals can support such work (longitudinal samples). At NCA we see many patients with neurodegenerative diseases, many of them will be at relatively early stage of their illness. CFU medical and psychology staff are well-practiced in participant recruitment for research, including dementia studies, and have considerable experience in consenting participants who lack capacity. They can identify suitable individuals and assess capacity. Potentially suitable participants who lack capacity to decide on inclusion in the project can be recruited using a consultee consent form. The biological samples collected will enable a number of different analyses to be performed. This may include (but not limited to): Genetic studies Biomarker studies Functional analysis of cells

The Northern Care Alliance Research Collection (NCARC) includes a biobank to explore novel application of laboratory biomarkers in Inherited Metabolic Diseases. The collection population comprises patients with rare metabolic diseases such as Mucopolysaccharidosis, Alpha-Mannosidosis, Mucolipidosis, Pompe Disease, Fabry Disease, Gaucher Disease, Phenylketonuria, Urea Cycle Disorders, Organic Acidaemia, mitochondrial diseases and many others. The collection consists of whole blood, serum, plasma and citrate plasma samples as well as associated clinical data from both primary and secondary care settings. The collection allows scope for adjustment to the sample type through NCARC’s simple amendment process. This collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research in establishing prognostic markers of cardiovascular disease, bone health, renal disease and acute illness among rare diseases. There is potential to improve the method and time taken for diagnosis, prognostication and treatment monitoring with refinement of laboratory processing and biomarker discovery. Our biological samples have been processed and stored under conditions that reflect the current best practise to maximise the integrity and security of the samples and ensure compliance with current regulatory requirements. The biological samples collected will enable a number of different analyses to be performed. This may include (but not limited to): • Biomarker studies • Multi-morbidity studies • Biomedical device development

The Northern Care Alliance Research Collection (NCARC) includes a biobank to explore novel application of laboratory biomarkers in Inherited Metabolic Diseases. The collection population comprises patients with rare metabolic diseases such as Mucopolysaccharidosis, Alpha-Mannosidosis, Mucolipidosis, Pompe Disease, Fabry Disease, Gaucher Disease, Phenylketonuria, Urea Cycle Disorders, Organic Acidaemia, mitochondrial diseases and many others. The collection consists of whole blood, serum, plasma and citrate plasma samples as well as associated clinical data from both primary and secondary care settings. The collection allows scope for adjustment to the sample type through NCARC’s simple amendment process. This collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research in establishing prognostic markers of cardiovascular disease, bone health, renal disease and acute illness among rare diseases. There is potential to improve the method and time taken for diagnosis, prognostication and treatment monitoring with refinement of laboratory processing and biomarker discovery. Our biological samples have been processed and stored under conditions that reflect the current best practise to maximise the integrity and security of the samples and ensure compliance with current regulatory requirements. The biological samples collected will enable a number of different analyses to be performed. This may include (but not limited to): • Biomarker studies • Multi-morbidity studies • Biomedical device development

The Northern Care Alliance Research Collection (NCARC) includes a biobank to explore novel application of laboratory biomarkers in Inherited Metabolic Diseases. The collection population comprises patients with rare metabolic diseases such as Mucopolysaccharidosis, Alpha-Mannosidosis, Mucolipidosis, Pompe Disease, Fabry Disease, Gaucher Disease, Phenylketonuria, Urea Cycle Disorders, Organic Acidaemia, mitochondrial diseases and many others. The collection consists of whole blood, serum, plasma and citrate plasma samples as well as associated clinical data from both primary and secondary care settings. The collection allows scope for adjustment to the sample type through NCARC’s simple amendment process. This collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research in establishing prognostic markers of cardiovascular disease, bone health, renal disease and acute illness among rare diseases. There is potential to improve the method and time taken for diagnosis, prognostication and treatment monitoring with refinement of laboratory processing and biomarker discovery. Our biological samples have been processed and stored under conditions that reflect the current best practise to maximise the integrity and security of the samples and ensure compliance with current regulatory requirements. The biological samples collected will enable a number of different analyses to be performed. This may include (but not limited to): • Biomarker studies • Multi-morbidity studies • Biomedical device development

The Northern Care Alliance Research Collection (NCARC) includes a biobank to explore novel application of laboratory biomarkers in Inherited Metabolic Diseases. The collection population comprises patients with rare metabolic diseases such as Mucopolysaccharidosis, Alpha-Mannosidosis, Mucolipidosis, Pompe Disease, Fabry Disease, Gaucher Disease, Phenylketonuria, Urea Cycle Disorders, Organic Acidaemia, mitochondrial diseases and many others. The collection consists of whole blood, serum, plasma and citrate plasma samples as well as associated clinical data from both primary and secondary care settings. The collection allows scope for adjustment to the sample type through NCARC’s simple amendment process. This collection aims to promote biomedical research by providing biomaterial to academic and commercial researchers/partners to facilitate high-quality research in establishing prognostic markers of cardiovascular disease, bone health, renal disease and acute illness among rare diseases. There is potential to improve the method and time taken for diagnosis, prognostication and treatment monitoring with refinement of laboratory processing and biomarker discovery. Our biological samples have been processed and stored under conditions that reflect the current best practise to maximise the integrity and security of the samples and ensure compliance with current regulatory requirements. The biological samples collected will enable a number of different analyses to be performed. This may include (but not limited to): • Biomarker studies • Multi-morbidity studies • Biomedical device development